Ekso Bionics (NASDAQ:EKSO – Get Free Report) and TransMedics Group (NASDAQ:TMDX – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Profitability
This table compares Ekso Bionics and TransMedics Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ekso Bionics | -70.74% | -90.71% | -42.25% |
| TransMedics Group | 16.20% | 31.42% | 10.55% |
Analyst Ratings
This is a summary of current recommendations for Ekso Bionics and TransMedics Group, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ekso Bionics | 1 | 0 | 2 | 0 | 2.33 |
| TransMedics Group | 0 | 5 | 7 | 0 | 2.58 |
Earnings & Valuation
This table compares Ekso Bionics and TransMedics Group”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ekso Bionics | $14.75 million | 0.84 | -$11.33 million | ($5.68) | -0.83 |
| TransMedics Group | $441.54 million | 11.64 | $35.46 million | $2.47 | 60.90 |
TransMedics Group has higher revenue and earnings than Ekso Bionics. Ekso Bionics is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
6.4% of Ekso Bionics shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 6.0% of Ekso Bionics shares are owned by company insiders. Comparatively, 7.0% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Ekso Bionics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500.
Summary
TransMedics Group beats Ekso Bionics on 13 of the 14 factors compared between the two stocks.
About Ekso Bionics
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
About TransMedics Group
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
